Startseite › Metastasierender Krebs › Illinois › Chicago
Klinische Studien zu Metastasierender Krebs in Chicago, IL
45 Studien zu Metastasierender Krebs suchen Teilnehmer an Standorten in und um Chicago (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Teilnehmer gesuchtPhase 2
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- und 3 weitere
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Chicago Hospital, Chicago
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Teilnehmer gesuchtPhase 3
- City of Hope, Chicago
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Teilnehmer gesuchtPhase 1
- Northwestern University, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
Teilnehmer gesuchtPhase 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Teilnehmer gesuchtPhase 3
- Illinois Cancer Specialists, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Teilnehmer gesuchtPhase 3
- Research Site, Chicago
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Teilnehmer gesuchtPhase 1/2
- University of Chicago, Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Teilnehmer gesuchtPhase 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Teilnehmer gesuchtPhase 3
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Teilnehmer gesuchtPhase 3
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- The University of Chicago Medicine, Chicago
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago
CREO - Microwave Ablation Feasibility Study
Teilnehmer gesucht
- Rush University Medical Center, Chicago
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Teilnehmer gesuchtPhase 1
- Northwestern University ( Site 0101), Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Teilnehmer gesuchtPhase 2
- Northwestern University, Chicago
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Teilnehmer gesuchtPhase 3
- Northwestern University, Chicago
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Teilnehmer gesuchtPhase 1/2
- Northwestern University, Chicago
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Teilnehmer gesuchtPhase 1
- The University of Chicago Medical Center (UCMC), Chicago
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Teilnehmer gesuchtPhase 2
- Research Site, Chicago
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Teilnehmer gesuchtPhase 1
- University of Chicago Comprehensive Cancer Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Teilnehmer gesuchtPhase 3
- Research Site, Chicago
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- The University of Chicago Medicine, Chicago
A Study of PYX-201 in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Chicago Medicine, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
Teilnehmer gesuchtPhase 1
- The University of Chicago Medical Center (UCMC), Chicago
REMASTer: REcurrent Brain Metastases After SRS Trial
Teilnehmer gesucht
- University of Chicago, Chicago
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Teilnehmer gesuchtPhase 3
- Northwestern University, Chicago
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Teilnehmer gesuchtPhase 1
- Context Investigational Site, Chicago
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Teilnehmer gesuchtPhase 2
- Northwestern University, Chicago
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Teilnehmer gesuchtPhase 1/2
- University of Chicago Medical Center, Chicago
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Teilnehmer gesuchtPhase 1/2
- University of Chicago, Chicago
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Teilnehmer gesuchtPhase 3
- University of Illinois Cancer Center, Chicago
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Teilnehmer gesuchtPhase 2/3
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Teilnehmer gesuchtPhase 1
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Teilnehmer gesuchtBeobachtungsstudie
- John H Stroger Jr Hospital of Cook County, Chicago
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
Teilnehmer gesuchtPhase 1
- University of Illinois at Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Teilnehmer gesuchtPhase 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Teilnehmer gesuchtPhase 3
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Teilnehmer gesuchtPhase 1
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Chicago
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Teilnehmer gesuchtPhase 1
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Teilnehmer gesuchtPhase 1
- Northwestern University, Chicago
- University of Illinois, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Teilnehmer gesuchtPhase 1
- University of Chicago, Chicago
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Northwestern University, Chicago
Metastasierender Krebs-Studien in anderen Städten
- Houston, TX104 Studien
- New York City, NY93 Studien
- Nashville, TN70 Studien
- Boston, MA63 Studien
- Los Angeles, CA57 Studien
- St. Louis, MO54 Studien
- Arlington, VA53 Studien
- Philadelphia, PA46 Studien
- San Antonio, TX44 Studien
- Washington, DC43 Studien
- Dallas, TX42 Studien
- Seattle, WA39 Studien
Weitere Studien in Chicago
- Nichtkleinzelliges Lungenkarzinom61 Studien
- Brustkrebs58 Studien
- Krebs (alle Arten)51 Studien
- Prostatakrebs45 Studien
- Adipositas41 Studien
- Lungenkrebs41 Studien
- Eierstockkrebs36 Studien
- Schlaganfall34 Studien
- Kolorektales Karzinom33 Studien
- Herzinsuffizienz31 Studien
- Übergewicht28 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich26 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.